## From Old Age to Space Age Networks

Rupert McShane

Consultant in Old Age Psychiatry Honorary Senior Clinical Lecturer



#### **Networks**

DeNDRoN: Dementia & Neurodegenerative Diseases Recruitment

> Oxford Academic Health Science Network Innovation Reducing unwarranted variation

# NIHR 'portfolio': new recruits with dementia 2013-14 to date

Study	ID	Number	
Brain donation	BDR	50/87 <sup>tv</sup> /638 <sup>cum</sup>	
Vision assessment	PROVIDE	50/106 <sup>tv</sup> /165 <sup>cum</sup>	
Exercise in dementia - RCT	DAPA	52/90 <sup>tv</sup>	
Stem cells	STEMBANCC	27	
Assistive Technology – Qualitative	AKTIVE	2	
Assistive Technology – RCT	ATILLA	14	
Functional MRI - diagnostic		112	
Training in person centred care – care home RCT	WHELD	324	
Commercial, multicentre, drug RCT	SERVIER	9	
Commercial, multicentre, drug RCT	MERCK EPOCH	5	
Commercial, multicentre, drug RCT	TAU Rx	0	
OXON + BUCKS TOTAL: 656 OXON TOTAL (est): 460			

tv: TV total cum: cumulative total all years

#### Other major clinical research

- Oxford Vascular Cognitive Impairment Cohort
  - 2000 patient subset of OXVASC
    - Incidence & risk factors following stroke / vascular
- Parkinson's UK Discovery
- Healthy elderly
  - 800 civil servants followed for >25y
    - Cognitive reserve, structure & connections
  - Exercise and cognitive stimulation
    - Effect in healthy ageing

### Performance against PM 10% target

- % diagnosed in Oxon
  - -460/2,500 = 18.4%
- % Expected prevalence in Oxon
  - -460/7,757 = 5.9%



#### 'Join Dementia Research'

- New national IT system in development
- Who is active on our 'Research Interested Lists'?
  - Oxon, Dementia: 363
  - Oxon, Dementia, in current study: 87

#### **Original Investigation**

## Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

#### The TEAM-AD VA Cooperative Randomized Trial

Maurice W. Dysken, MD; Mary Sano, PhD; Sanjay Asthana, MD; Julia E. Vertrees, PharmD, BCPP; Muralidhar Pallaki, MD; Maria Llorente, MD; Susan Love, MA; Gerard D. Schellenberg, PhD; J. Riley McCarten, MD; Julie Malphurs, PhD; Susana Prieto, MD; Peijun Chen, MD, MPH, PhD; David J. Loreck, MD; George Trapp, MD, JD; Rajbir S. Bakshi, MD; Jacobo E. Mintzer, MD; Judith L. Heidebrink, MD; Ana Vidal-Cardona, MD; Lillian M. Arroyo, MD; Angel R. Cruz, MD; Sally Zachariah, MD; Neil W. Kowall, MD; Mohit P. Chopra, MD; Suzanne Craft, PhD; Stephen Thielke, MD; Carolyn L. Turvey, PhD; Catherine Woodman, MD; Kimberly A. Monnell, MD; Kimberly Gordon, MSN, RN, FNP-BC; Julie Tomaska, PhD; Yoav Segal, MD, PhD; Peter N. Peduzzi, PhD; Peter D. Guarino, MPH, PhD

JAMA. 2014;311(1):33-44. doi:10.1001/jama.2013.282834

•No industry involvement

- Veterans with possible or probable AD
- mild to moderate severity
  - MMSE 12-26 inclusive
- Currently taking a ChEI eg Donepezil

#### Design

- Factorial ~N=150 in each arm
  - Vitamin E 1000iu bd
  - Memantine 10mg bd
  - Memantine 10mg bd + Vitamin E 1000iu bd
  - Placebo
- Vitamin E: DL-alpha-tocopheral acetate 'synthetic
- Follow up 2.3 years

- Average age ~78y
- Mean MMSE 21
- 30% start within 12 weeks of starting ChEI
- Follow up 2.3 years

#### Outcomes

- Primary: Alzheimer's Disease Cooperative Study-ADL
- Secondary
  - MMSE
  - ADASCog
  - Neuropsychiatry Inventory (Freq x Sev)
  - Caregiver Activity Survey
    - Time spent assisting in 6 ADL domains
  - Dependence Scale
    - 6 levels of functional dependence

#### Main result

Compared with placebo

<ul> <li>3.15 ADCS points less decline</li> </ul>	on Vitamin E
<b>- 1.98</b>	on memantine
<b>- 1.76</b>	on both

- Delays progression by
  - 19% per year
- Comparable to ChEI eg Donepezil / Aricept
- Reduced caregiver time by 2 hours per day

## A previous Vitamin E study

- Vit E (1,000iu bd) vs Selegiline (10mg od) vs both vs placebo
- 2 years
- N=341, (~85 in each group)
- Mean MMSE = 13
- Mean age = 73y
- Primary outcome: time to any of
  - Death
  - Institutionalisation
  - Loss of 2 of eating, grooming, toilet
  - Severe dementia

Sano et al, 1997, NEngJMed 336:1216-22


## Vitamin E – useful evidence?

Outcome	Placebo	Vit E
Unadjusted 'survival' (days)*	526	597
Adjusted 'survival' (days)*	440	670
Loss of ADL (%)	31	22
Severe dementia (%)	51	48
Institutionalisation (%)	39	26
Death (%)	12	12

<sup>\*</sup> To composite endpoint

Of course I've taken my pills, darling

Cuprous Chloride ~10  $\mu m$ 



Magnesium ~10 μm







#### your password?








teusdigitalhealth.com/helius-app-0.99.20130918/helius.jsp

to save your password?










password?


#### helius<sup>\_</sup>







### helius<sup>\_</sup>








# Circle of Care If only I'd known THAT

#### The online version of your personal child health record



▼ Rupert McShane

Health Professional Sign In

Home

**Health Record** 


**Healthy Child Programme** 

**Growth and Development** 

Information

Contacts







Age: 13 days Gender: Unknown

Born: 05/03/2014

Calendar

Most Recent Weight: None

entered

Photos of BAby

**Summary & Appointments** 

Screening & Routine Reviews

**Immunisations** 


Notes

**Growth Charts & Firsts** 


#### Contacts

Use this space to save important clinical contacts.

You have not yet added any contacts. Add contacts



'Jointly'
Carers UK
Circle of care



#### **Joan Smith** Joan Smith ☆ Home Invite people to this circle See who is in this circle ♣ Joan's profile Michelle Townsend Messages Rupert McShane (you) ✓ Tasks Pending invitations math Calendar No pending invitations in this circle. (a) Medications Recent circle activity you commented Beware parking is an absolute nightmare. Come Contacts earlier. Might be worth... Circle settings Mou created Memory clinic for Thursday, 13th of March Your Jointly circles You created Donepezil Joan Smith Michelle joined this circle Senior McShane You joined this circle You created this circle + Create a new circle Rupert McShane About you

